CJC-1295 & Ipamorelin

CJC-1295 & Ipamorelin Overview

CJC-1295 & Ipamorelin combines two peptides commonly studied in growth hormone pathway research. CJC-1295 is studied as a growth hormone-releasing hormone analogue, while Ipamorelin is studied for selective ghrelin receptor activity. As a blend, they are used to examine how these signaling pathways interact within the same experimental system.

Mechanism of Action & Applications

CJC-1295 & Ipamorelin is studied through two complementary mechanisms. CJC-1295 is used to examine GHRH receptor-mediated signaling, while Ipamorelin is used to examine ghrelin receptor, or growth hormone secretagogue receptor, activity. In research models, this makes the blend useful for studying coordinated pituitary signaling, growth hormone pulse dynamics, receptor cross-talk, and broader endocrine pathway behavior. It is commonly used in studies involving GHRH biology, ghrelin pathway activity, peptide signaling coordination, and growth hormone axis research.

Research History

This blend builds on earlier research into GHRH analogues and growth hormone secretagogues. CJC-1295 emerged from work focused on extending GHRH activity, while Ipamorelin developed as a more selective ghrelin receptor agonist within the GHS class. Combined formulations later became common in research settings where both pathways were studied together rather than in isolation.

Chemical Information (CJC-1295)

CAS Number

446262-90-4

Molecular Formula

C₁₆₅H₂₆₉N₄₇O₄₆

Molecular Weight

3,647.2 g/mol

Chemical Information (Ipamorelin)

CAS Number

170851-70-4

Molecular Formula

C₃₈H₄₉N₉O₅

Molecular Weight

711.85 g/mol